Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy

Discovery Medicine

Volumn 20, Issue 108, 2015, Pages 67-77

  Wang, Chunyi ^a   Min, Cunyun ^b   Rong, Xianglu ^a   Fu, Tingting ^b   Huang, Xuhui ^b   Wang, Changjun ^b  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; FATTY ACID; GLUCOSE; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIPHENYL DERIVATIVE; CREATININE; LIPID; NITROGEN; TETRAZOLE DERIVATIVE; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HISTOLOGY; INSULIN BLOOD LEVEL; KIDNEY BIOPSY; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; RENAL PROTECTION; URINALYSIS; ANIMAL; BLOOD; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; KIDNEY; METABOLISM; URINE;

ANIMALS; BIPHENYL COMPOUNDS; CHRONIC DISEASE; CREATININE; DIABETIC NEPHROPATHIES; KIDNEY; LIPIDS; MALE; MICE; NITROGEN; TETRAZOLES; URIC ACID;

EID: 84940856140     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Balakumar P, Varatharajan R, Nyo YH, Renushia R, Raaginey D, Oh AN, et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 90:36-47, 2014.
2. Bulum T, Kolarić B, Prkacin I, Duvnjak L. Total and LDL cholesterol are associated with glomerular filtration rate in normoalbuminuric type 1 diabetic patients. Coll Antropol 37(3):771-776, 2013.
3. Chaipichit N, Krska J, Pratipanawatr T, Jarernsiripornkul N. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries. Int J Clin Pharm, epub ahead of print, Jan. 29, 2015.
4. Chen SC, Hung CC, Kuo MC, Lee JJ, Chiu YW, Chang JM, et al. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoS One 8(2):e55643, 2013.
5. Conway BR, Betz B, Sheldrake TA, Manning JR, Dunbar DR, Dobyns A, et al. Tight blood glycaemic and blood pressure control in experimental diabetic nephropathy reduces extracellular matrix production without regression of fibrosis. Nephrology (Carlton) 19(12):802-813, 2014.
6. Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant 26(1):28-35, 2011.
7. Gaballa M, Farag MK. Predictors of diabetic nephropathy. Eur J Med 8:287-296, 2013.
8. Gotoh K, Masaki T, Chiba S, Ando H, Fujiwara K, Shimasaki T, et al. Effects of hydrophilic statins on renal tubular lipid accumulation in diet-induced obese mice. Obes Res Clin Pract 7(5):e342-e352, 2013.
9. Hartner A, Cordasic N, Klanke B, Menendez-Castro C, Veelken R, Schmieder RE, et al. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. Biochim Biophys Acta 1842(4):558-565, 2014.
10. Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 55(3):561-572, 2014.
11. Hu ZJ, Ren LP, Wang C, Liu B, Song GY. Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes. Exp Ther Med 8(3):951-956, 2014.
12. Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21(1):37-46, 2015.
13. Kassimatis TI, Goldsmith DJ. Statins in chronic kidney disease and kidney transplantation. Pharmacol Res 88:62-73, 2014.
14. Lee HS. Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome. Histol Histopathol 26(12):1599-1610, 2011.
15. Lezcano EJ, Iñigo P, Larraga AM, Barranquero C, Gimenez I, Osada J. Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats. Diabetol Metab Syndr 6(1):10, 2014.
16. Ma KL, Ni J, Wang CX, Liu J, Zhang Y, Wu Y, et al. Interaction of RAS activation and lipid disorders accelerates the progression of glomerulosclerosis. Int J Med Sci 10(12):1615-1624, 2013.
17. Magni P, Macchi C, Morlotti B, Sirtori CR, Ruscica M. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med 26(2):82-88, 2015.
18. Merscher S, Pedigo CE, Mendez AJ. Metabolism, energetics, and lipid biology in the podocyte cellular cholesterol-mediated glomerular injury. Front Endocrinol (Lausanne) 14(5):169, 2014.
19. Morrison FJ, Zhang H, Skentzos S, Shubina M, Bentley-Lewis R, Turchin A. Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease. Cardiorenal Med 4(3-4):225-233, 2014.
20. Moriyama T, Oshima Y, Tanaka K, Iwasaki C, Ochi A, Itabashi M, et al. Statins stabilize the renal function of IgA nephropathy. Ren Fail 36(3):356-360, 2014.
21. Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol 6:79-86, 2014.
22. Oshima Y, Morimoto S, Ichihara A. Roles of the (pro)renin receptor in the kidney. World J Nephrol 3(4):302-307, 2014.
23. Ozawa S, Ueda S, Li Y, Mori K, Asanuma K, Yanagita M, et al. Fatty acid binding protein 3 as a potential mediator for diabetic nephropathy in eNOS deficient mouse. Biochem Biophys Res Commun 454(4):531-536, 2014.
24. Ros-Ruiz S, Aranda-Lara P, Fernández JC, Martínez-Esteban MD, Jironda C, Hidalgo P, et al. High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy. Clin Pharmacol 6:79-86, 2014.
25. Rysz J, Gluba-Brzózka A, Banach M, Wiecek A. Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. Int Urol Nephrol, epub ahead of print, Mar. 11, 2015.
26. Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129(9):999-1008, 2014.
27. Shiraishi T, Tamura Y, Taniguchi K, Higaki M, Ueda S, Shima T, et al. Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease. Am J Physiol Renal Physiol 307(12):F1313-F1322, 2014.
28. Tsun JG, Yung S, Chau MK, Shiu SW, Chan TM, Tan KC. Cellular cholesterol transport proteins in diabetic nephropathy. PLoS One 9(9):e105787, 2014.
29. Weir MR. Salt, hypertension, and proteinuria in diabetic nephropathy. Lancet Diabetes Endocrinol 2(5):351-352, 2014.
30. Witzel SH, Butts K, Filler G. Elevated triglycerides may affect cystatin C recovery. Clin Biochem 47(7-8):676-678, 2014.
31. Xu Y, Huang J, Xin W, Chen L, Zhao X, Lv Z, et al. Lipid accumulation is ahead of epithelial-to-mesenchymal transition and therapeutic intervention by acetyl-CoA carboxylase 2 silence in diabetic nephropathy. Metabolism 63(5):716-726, 2014.
32. Yasuda M, Tanaka Y, Kume S, Morita Y, Chin-Kanasaki M, Araki H, et al. Fatty acids are novel nutrient factors to regulate mTORC1 lysosomal localization and apoptosis in podocytes. Biochim Biophys Acta 1842(7):1097-1108, 2014.